Overall tolerabilityNo significant difference
The addition of S. boulardii to traditional therapy significantly improved the H. pylori eradication rate [RR=1.11, 95% confidence interval (CI): 1.08-1.15] and reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37-0.66)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication abdominal distensionNo significant differenceRR=0.49, 95% CI: 0.33-0.72
abdominal distension (RR=0.49, 95% CI: 0.33-0.72)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication abdominal gasNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pyloabdominal painNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication constipationNo significant differenceRR=0.38, 95% CI: 0.26-0.57
constipation (RR=0.38, 95% CI: 0.26-0.57)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication diarrheaNo significant differenceRR=0.36, 95% CI: 0.26-0.48
reduced the incidence of total adverse effects (RR=0.49, 95% CI: 0.37-0.66), diarrhea (RR=0.36, 95% CI: 0.26-0.48)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication diarrheaNo significant difference14.5% vs 30.6%
Nine (14.5%) patients in the treatment group and 19 (30.6%) patients in the placebo group experienced diarrhea (p < .05).
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylodiffuse abdominal painNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pyloepigastric discomfortNo significant difference14.5% vs 43.5%
Epigastric discomfort was more frequent in the control group [9 (14.5%) versus 27 (43.5%), respectively (p < .01)].
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylonauseaNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylonauseaNo significant differenceRR=0.50, 95% CI: 0.37-0.68
nausea (RR=0.50, 95% CI: 0.37-0.68)
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication taste disordersNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication taste disturbanceNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylourticariaNo significant difference
Diffuse abdominal pain, abdominal gas, taste disturbance, urticaria, nausea symptoms were similar in both groups.
from: Efficacy and Safety of Saccharomyces boulardii in the 14‐day Triple Anti‐Helicobacter pylovomitingNo significant difference
However, it did not reduce the occurrence of abdominal pain, vomiting, or taste disorders.
from: Efficacy and safety of Saccharomyces boulardii as an adjuvant therapy for the eradication adverse eventsReported
The incidence of adverse events was significantly lower in the VAS group (11.6%) than it was in the VA group (32.6%; P < 0.001).
from: Vonoprazan-Amoxicillin Dual Therapy with or Without Saccharomyces boulardii Supplementatio